首页 > 市场调查报告书 > 医疗设备

体外诊断癌症

市场调查报告书

商品编码

1542917

全球循环肿瘤细胞 (CTC) 市场 - 2024-2031

Global Circulating Tumor Cells (CTC) Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

循环肿瘤细胞市场规模

全球循环肿瘤细胞市场在2023年达到118亿美元，预计到2031年将达到266.1亿美元，在2024-2031年预测期间复合年增长率为11.1%。

循环肿瘤细胞（CTC）是从原发肿瘤脱落并进入周边血液循环系统并导致转移的肿瘤细胞。从临床样本中灵敏检测 CTC 可作为透过液体活检进行癌症诊断和预后的有效工具。

目前的CTC检测技术主要依赖生物标记介导的平台，包括磁珠、微流控晶片或尺寸敏感的微滤，这些平台可能会因肿瘤异质性而降低检测灵敏度。最近开发了一种更灵敏、不依赖生物标记的 CTC 分离技术，该技术使用表面带电的超顺磁性奈米探针，能够从 1 mL 临床血液中捕获不同的 EMT 亚群 CTC。

循环肿瘤细胞市场的驱动因素与限制

癌症病例数不断增加

癌症病例数的增加是预测期内帮助市场成长的重要关键因素之一。例如，根据国家卫生统计中心的数据。 2023 年，美国预计将出现 1,958,310 例新癌症病例和 609,820 例癌症死亡。前列腺癌的发生率在经历了二十年的下降之后，从 2014 年到 2019 年每年增加 3%，意味着新增病例增加了 99,000 例；然而，除此之外，男性的发生率趋势比女性更为有利。

随着癌症盛行率的上升，对有效的癌症诊断和监测工具以及基于 CTC 的检测和技术的需求不断增长。这为市场上的公司开发创新产品和解决方案提供了重要机会，以实现 CTC 的检测、计数和分子表征。

此外，人们对液体活检方法日益增长的兴趣进一步推动了对基于 CTC 的技术的需求，因为它们提供了一种即时监测癌症患者的非侵入性方法。

此外，循环肿瘤细胞市场也受到各种其他因素的推动，例如CTC检测技术的进步、对快速癌症诊断的需求不断增加、标靶治疗的开发等也将有助于市场在预测期内成长。

市场动态：

克制

预测期内阻碍市场成长的各种因素包括严格的监管架构、CTC检测的技术困难、成本控制措施、缺乏对先进CTC技术的了解以及产品上市审批的耗时要求。

循环肿瘤细胞细分市场分析

全球循环肿瘤细胞市场根据产品类型、技术、应用、样本、最终用户和地区进行细分。

从产品类型细分来看，器械细分市场约占循环肿瘤细胞市场份额的43.5%

该产品类型细分市场的设备约占 43.5%，预计在预测期内将占据主导地位。该部门专注于开发和利用专为 CTC 相关应用设计的设备。为了提高技术能力并促进大规模生产，市场上出现了製造玻璃微晶片，可以解决挑战并提高整体效率。

例如，2020 年 6 月，SCIENION AG 和 RareCyte Inc. 表示，cellenONE 被证明是在肿瘤学应用中精确单细胞分配少量模型循环肿瘤细胞 (CTC) 的最合适设备。 RareCyte 使用 SCIENIONO 法国子公司 Cellenion 的多功能技术，将预定数量的目标 CTC 精确且可重复地添加到血液样本中。

循环肿瘤细胞市场地域份额

2022年北美约占38.4%的市占率

据估计，在整个预测期内，北美将占据约38.4% 的总市场份额，原因是该地区癌症患病率不断上升，加上诊断技术的进步以及医疗保健专业人员意识的提高，促进了癌症的蓬勃发展。此外，强大的医疗基础设施，加上在研发方面的大量投资，为创新的 CTC 检测和分析技术铺平了道路。

例如，根据美国癌症协会2022年的估计，2022年该国将诊断出约236,740例新发肺癌病例。将报告肾癌。癌症的高负担预计将增加对 CTC 检测试剂盒的需求，从而推动市场成长。

COVID-19 影响分析

COVID-19 大流行对循环肿瘤细胞市场产生了重大影响。这场大流行造成了全球医疗保健系统的中断，导致癌症筛检、诊断和治疗的延误。这反过来又影响了对基于 CTC 的测试和技术的需求。此外，对非必要医疗程序的限制和患者就诊医疗机构的减少导致基于 CTC 的检测的采用率下降。

循环肿瘤细胞市场公司

该市场的主要全球参与者包括 Thermo Fisher Scientific Inc.、QIAGEN、Fluxion Biosciences, Inc.、Greiner Bio One International GmbH、Ikonisys Inc.、BioFluidica、Biolidics Limited、Creativ MicroTech Inc.、Menarini Silicon Biosystems、StemCell Technologies 等。

主要进展

2023 年 9 月，全球领先的液体活检公司 ANGLE plc 宣布推出其 Portrait (TM) Flex CTC 检测方法，该公司为肿瘤研究和诊断市场提供创新的循环肿瘤细胞 (CTC) 诊断解决方案。此检测由 ANGLE 符合 GCP 标准的 Onc-ADaPT (TM) 实验室提供，并由在 CTC 分析方面拥有 10 多年经验的专家团队进行。

2023 年 7 月，液体活检和单细胞技术先驱 Menarini Silicon Biosystems (MSB) 表示，其新的 CELLSEARCH CTC 实验室服务可用于检测肿瘤细胞中 Delta 样配体 3 (DLL3) 蛋白的表达在血液中循环。此生物标记主要在难以治疗的癌症中表现。新的 MSB 实验室服务为开发进一步的微创测试打开了大门，这些测试在需求未满足的医疗环境中利用生物标记的预后和预测价值。

2021年5月，ARUP实验室表示，已与总部位于麻萨诸塞州的TellBio Inc.签署策略协议，在多项研究应用中使用该开发阶段生物技术公司的TellDx循环肿瘤细胞（CTC）技术。

为什么购买报告？

根据产品类型、技术、应用、样本、最终用户和地区可视化全球循环肿瘤细胞市场细分，并了解关键商业资产和参与者。

透过分析趋势和共同开发来识别商业机会。

Excel资料表包含所有细分市场层级的循环肿瘤细胞的大量资料点。

PDF 报告由详尽的质性访谈和深入研究后的综合分析组成。

产品映射以 Excel 形式提供，包含所有主要参与者的关键产品。

全球循环肿瘤细胞市场报告将提供约 77 个表格、79 个图表和 187 页。

2024 年目标受众

製造商/买家

产业投资者/投资银行家

研究专业人员

新兴公司

Circulating tumor cells (CTCs) are tumor cells that shed from the primary tumor and intravasate into the peripheral blood circulation system responsible for metastasis. Sensitive detection of CTCs from clinical samples can serve as an effective tool in cancer diagnosis and prognosis through liquid biopsy.

Current CTC detection technologies mainly reply on biomarker-mediated platforms including magnetic beads, microfluidic chips or size-sensitive microfiltration which can compromise detection sensitivity due to tumour heterogeneity. A more sensitive, biomarker-independent CTCs isolation technique has been recently developed with the surface-charged superparamagnetic nanoprobe capable of different EMT subpopulation CTC capture from 1 mL clinical blood.

Circulating Tumor Cells Market Drivers and Restraints

Increasing number of cancer cases

The increasing number of cancer cases is one of the significant key factors that help the market to grow during the forecast period. For instance, according to the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases; otherwise, however, incidence trends were more favourable in men compared to women.

As cancer prevalence rises, there is a growing need for effective cancer diagnostics and monitoring tools along with CTC-based assays and technologies. This presents a significant opportunity for companies operating in the market to develop innovative products and solutions that enable the detection, enumeration, and molecular characterization of CTCs.

Additionally, the growing interest in liquid biopsy approaches further fuels the demand for CTC-based technologies, as they offer a non-invasive method for real-time monitoring of cancer patients.

Furthermore, the circulating tumor cells market is also driven by various other factors like, advancements in CTC detection technologies, increasing demand for rapid cancer diagnosis, development of targeted therapies and others will also help the market to grow during the forecast period.

Market Dynamics: Restraint

Various factors which hamper the market growth during the forecast period some which are Stringent regulatory framework, technical difficulties in CTC detection, cost containment measures, lack of knowledge about advanced CTC technologies, and time-consuming requirements for product launch approvals.

Circulating Tumor Cells Market Segment Analysis

The global circulating tumor cells market is segmented based on product type, technology, application, specimen, end user and region.

The devices segment from the product type segment accounted for approximately 43.5% of the circulating tumor cells market share

The devices from the product type segment accounted for approximately 43.5% and are expected to be dominated during the forecast period. This segment focuses on developing and utilizing devices specifically designed for CTC-related applications. To enhance technical capabilities and facilitate mass production, the market has witnessed the introduction of manufactured glass microchips, which address challenges and improve overall efficiency.

For instance, in June 2020, SCIENION AG and RareCyte Inc. stated that cellenONE proved to be the most appropriate device for accurate single-cell dispensing of low numbers of model circulating tumor cells (CTCs) in oncology applications. RareCyte uses the versatile technology of SCIENIONOs French subsidiary Cellenion for precise and reproducible dosing of a predefined number of targeted CTCs into blood samples.

Circulating Tumor Cells Market Geographical Share

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to factors like the increasing prevalence of cancer in the region coupled with advancements in diagnostic technologies as well as rising awareness among healthcare professionals has contributed to the flourishing CTCs market. Also, robust healthcare infrastructure, coupled with significant investments in research and development, has paved the way for innovative CTC detection and analysis techniques.

For instance, according to the estimates of the 2022, American Cancer Society, Inc., about 236,740 new cases of lung cancer will be diagnosed in the country in 2022. The same source also states that 79,000 new cases of kidney cancer and 13,920 deaths will be reported in 2022 from kidney cancer. The high burden of cancer is expected to boost the demand for CTC detection kits, thereby driving market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic had a significant impact on the circulating tumor cells market. The pandemic caused disruptions in healthcare systems worldwide, leading to delays in cancer screenings, diagnosis, and treatment. This, in turn, affected the demand for CTC-based tests and technologies. Moreover, restrictions on non-essential medical procedures and reduced patient visits to healthcare facilities resulted in a decline in the adoption of CTC-based assays.

Circulating Tumor Cells Market Companies

The major global players in the market include Thermo Fisher Scientific Inc, QIAGEN, Fluxion Biosciences, Inc., Greiner Bio One International GmbH, Ikonisys Inc., BioFluidica, Biolidics Limited, Creativ MicroTech Inc., Menarini Silicon Biosystems, StemCell Technologies among others.

Key Developments

In September 2023, ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumor cell (CTC) diagnostic solutions for the research and diagnostic oncology market, stated the launch of its Portrait™ Flex CTC assay. The assay is provided as a service from ANGLE's Onc-ADaPT™ GCP-compliant laboratories and conducted by an expert team with over 10 years of experience in CTC analysis.

In July 2023, Menarini Silicon Biosystems (MSB), a pioneer in liquid biopsy and single-cell technologies, stated the availability of its new CELLSEARCH CTC lab service to detect the expression of the Delta-Like Ligand 3 (DLL3) protein in tumor cells circulating in the bloodstream. This biomarker is mainly expressed in difficult-to-treat cancers. The new MSB lab service opens the door to the development of further minimally invasive tests that leverage the prognostic and predictive value of biomarkers in medical settings with high unmet needs.

In May 2021, ARUP Laboratories stated that it had signed a strategic agreement with Massachusetts-based TellBio Inc. to use the development-stage biotechnology company's TellDx circulating tumor cells (CTCs) technology in several research applications.

Why Purchase the Report?

To visualize the global circulating tumor cells market segmentation based on product type, technology, application, specimen, end user and region as well as understand key commercial assets and players.

Identify commercial opportunities by analysing trends and co-development.

Excel data sheet with numerous data points of circulating tumor cells market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global circulating tumor cells market report would provide approximately 77 tables, 79 figures and 187 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Technology
3.3. Snippet by Application
3.4. Snippet by Specimen
3.5. Snippet by End User
3.6. Snippet by Region

4. Market Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing number of cancer cases
  - 4.1.1.2. Advancements in CTC detection technologies
- 4.1.2. Restraints
  - 4.1.2.1. Stringent regulatory approvals
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Devices*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Kits & Assays
7.4. Consumables

8. By Technology

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.1.2. Market Attractiveness Index, By Technology
8.2. CTC Detection and Enrichment Method*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. CTC Direct Detection Method
8.4. CTC Analysis

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Liquid Biopsy*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Research
9.4. Clinical
9.5. Others

10. By Specimen

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
- 10.1.2. Market Attractiveness Index, By Specimen
10.2. Blood*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Bone Marrow
10.4. Others

11. By End User

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.1.2. Market Attractiveness Index, By End User
11.2. Hospitals*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Clinics
11.4. Diagnostic Centers

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
- 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.2.8.1. U.S.
  - 12.2.8.2. Canada
  - 12.2.8.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
- 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.3.8.1. Germany
  - 12.3.8.2. UK
  - 12.3.8.3. France
  - 12.3.8.4. Italy
  - 12.3.8.5. Spain
  - 12.3.8.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
- 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.4.8.1. Brazil
  - 12.4.8.2. Argentina
  - 12.4.8.3. Rest of South America
12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.5.7.1. China
  - 12.5.7.2. India
  - 12.5.7.3. Japan
  - 12.5.7.4. Australia
  - 12.5.7.5. Rest of Asia-Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Specimen
- 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis

14. Company Profiles

14.1. Thermo Fisher Scientific Inc *
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
14.2. QIAGEN
14.3. Fluxion Biosciences, Inc
14.4. Greiner Bio One International GmbH
14.5. Ikonisys Inc
14.6. BioFluidica
14.7. Biolidics Limited
14.8. Creativ MicroTech Inc
14.9. Menarini Silicon Biosystems
14.10. StemCell Technologies (LIST NOT EXHAUSTIVE)